Literature DB >> 26520895

Long-term prognostic value of IgM antibodies against phosphorylcholine for adverse cardiovascular events in patients with stable coronary heart disease.

Armin Imhof1, Wolfgang Koenig2, Andrea Jaensch3, Ute Mons4, Hermann Brenner4, Dietrich Rothenbacher5.   

Abstract

BACKGROUND: Low concentrations of IgM-phosphorylcholine autoantibodies (IgM-anti-PC) have been shown to be associated with increased risk of incident cardiovascular disease (CVD) events and total mortality in patients suffering from an acute coronary syndrome. We assessed whether IgM-anti-PC concentrations add prognostic information for cardiovascular risk in patients with known stable coronary artery disease (CAD).
METHODS: IgM-anti-PC concentrations were measured in serum obtained from 1062 patients with clinically manifest stable CAD at baseline. The relation of IgM-anti PC concentrations with CVD events during long-term follow-up was assessed by the Kaplan-Meier and life table method and quantified by means of the log-rank test. Then, Cox proportional hazards regression analysis was performed to assess the independent association of IgM anti-PC concentration with risk of secondary CVD events after adjustment for established and emerging risk factors.
RESULTS: In n = 1062 patients with stable CAD only very low IgM anti-PC serum concentrations were associated with increased risk for future fatal and non-fatal coronary events (n = 201 during median of 10 years of follow-up). Among patients with IgM anti-PC concentrations in the lowest decile, the partly adjusted hazard ratio for fatal and non-fatal coronary events was 1.60 (95% confidence interval (CI) 1.01-2.55) compared to the top quartile and 1.94 (95%-CI 1.18-3.18) after adjustment for multiple covariates.
CONCLUSION: In patients with stable CAD, very low concentrations of IgM anti-PC are associated with increased risk for fatal and non-fatal future coronary events and thus may add prognostic information to traditional cardiovascular risk factors among these patients.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Cardiovascular disease; IgM anti-PC; Inflammation; Prognostic markers

Mesh:

Substances:

Year:  2015        PMID: 26520895     DOI: 10.1016/j.atherosclerosis.2015.10.024

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Antibodies against neural antigens in patients with acute stroke: joint results of three independent cohort studies.

Authors:  Georg Royl; Tsafack Judicael Fokou; Rittika Chunder; Rakad Isa; Thomas F Münte; Klaus-Peter Wandinger; Markus Schwaninger; Oliver Herrmann; José Manuel Valdueza; Jan Brocke; Martin Willkomm; Dietrich Willemsen; Gerd U Auffarth; Swantje Mindorf; Britta Brix; Angel Chamorro; Anna Planas; Xabier Urra
Journal:  J Neurol       Date:  2019-07-29       Impact factor: 4.849

2.  IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases.

Authors:  Divya Thiagarajan; Nina Oparina; Susanna Lundström; Roman Zubarev; Jitong Sun; Marta Alarcon-Riquelme; Johan Frostegård
Journal:  Sci Rep       Date:  2020-07-03       Impact factor: 4.379

3.  Potential natural immunization against atherosclerosis in hibernating bears.

Authors:  Shailesh Kumar Samal; Ole Fröbert; Jonas Kindberg; Peter Stenvinkel; Johan Frostegård
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

4.  Antibodies against phosphorylcholine in hospitalized versus non-hospitalized obese subjects.

Authors:  Johan Frostegård; M Magnusson; Amra Jujić; J Korduner; H Holm; G Engström; E Bachus; P Bhattacharya; P M Nilsson
Journal:  Sci Rep       Date:  2021-10-12       Impact factor: 4.379

5.  Antibodies Against Phosphorylcholine Among 60-Year-Olds: Clinical Role and Simulated Interactions.

Authors:  Shailesh Kumar Samal; Pritam Kumar Panda; Max Vikström; Karin Leander; Ulf de Faire; Rajeev Ahuja; Johan Frostegård
Journal:  Front Cardiovasc Med       Date:  2022-04-11

6.  Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality.

Authors:  S K Samal; A R Qureshi; M Rahman; P Stenvinkel; J Frostegård
Journal:  Clin Exp Immunol       Date:  2020-05-18       Impact factor: 4.330

7.  Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events.

Authors:  Sofia Ajeganova; Maria L E Andersson; Johan Frostegård; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2021-07-27       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.